Last reviewed · How we verify
LM001
At a glance
| Generic name | LM001 |
|---|---|
| Also known as | Follitropin alfa |
| Sponsor | Alphamab Jilin Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia (PHASE2)
- Study on the Safety and Pharmacokinetics of LM001 and Gonal-F® in Healthy Women (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LM001 CI brief — competitive landscape report
- LM001 updates RSS · CI watch RSS
- Alphamab Jilin Co., Ltd. portfolio CI